Woodline Partners LP Bionomics Limited Transaction History

Woodline Partners LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$1.96 - $2.9 $1,442 - $2,134	-736 Reduced 1.33%	54,446 $119,000
Q1 2023 May 15, 2023	SELL	$1.8 - $4.7 $152,607 - $398,475	-84,782 Reduced 60.57%	55,182 $143,000
Q4 2022 Feb 14, 2023	SELL	$4.65 - $9.67 $4,849 - $10,085	-1,043 Reduced 0.74%	139,964 $650,000
Q2 2022 Aug 15, 2022	SELL	$6.5 - $9.97 $129,571 - $198,741	-19,934 Reduced 12.39%	141,007 $986,000
Q1 2022 May 16, 2022	SELL	$8.47 - $12.97 $8,486 - $12,995	-1,002 Reduced 0.62%	160,941 $1.37 Million
Q4 2021 Feb 14, 2022	BUY	$12.35 - $14.73 $2 Million - $2.39 Million	161,943 New	161,943 $2.03 Million

2.5M

Ticker BNOX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 7,518,620
Market Cap $33.5M
Description
Bionomics Limited, a clinical-stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers in Australia and the United States. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which has ...

Get notified when there are updates to the investment portfolio of Woodline Partners LP, based on Form 13F filings with the SEC.

Stay updated on Woodline Partners LP with notifications on news.